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Abstract
The aim of the current study was to reduce the clinically used supra-physiological dose of bone morphogenetic 
protein-2 (BMP-2) (usually 1.5 mg/mL), which carries the risk of adverse events, by using a more effective 
release system. A slow release system, based on an injectable hydrogel composed of BMP-2-loaded 
recombinant collagen-based microspheres and alginate, was previously developed. Time- and dose-dependent 
subcutaneous ectopic bone formation within this system and bone regeneration capacity in a calvarial 
defect model were investigated. BMP-2 doses of 10 µg, 3 µg and 1 µg per implant (50 µg/mL, 15 µg/mL and 
5 µg/mL, respectively) successfully induced ectopic bone formation subcutaneously in rats in a time- and 
dose-dependent manner, as shown by micro-computed tomography (µCT) and histology. In addition, the 
spatio-temporal control of BMP-2 retention was shown for 4 weeks in vivo by imaging of fluorescently-
labelled BMP-2. In the subcritical calvarial defect model, µCT revealed a higher bone volume for the 2 µg 
of BMP-2 per implant condition (50 µg/mL) as compared to the lower dose used (0.2 µg per implant, 5 µg/
mL). Complete defect bridging was obtained with 50 µg/mL BMP-2 after 8 weeks. The BMP-2 concentration 
of 5 µg/mL was not sufficient to heal a calvarial defect faster than the empty defect or biomaterial control 
without BMP-2. Overall, this injectable BMP-2 delivery system showed promising results with 50 µg/mL 
BMP-2 in both the ectopic and calvarial rat defect models, underling the potential of this composite hydrogel 
for bone regeneration therapies.
Keywords: Bone morphogenetic protein-2, slow release, injectable delivery system, ectopic bone formation 
model, calvarial bone defect model.
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Introduction
Autologous bone is widely used in bone grafting 
surgery. However, its limited availability and the 
discomfort related to the harvesting procedure have 
diverted the field to seek for alternative methods 
involving biomaterials (Polo-Corrales et al., 2014). 
Bone morphogenetic proteins (BMP-2 and BMP-7), 
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being successful in inducing bone formation, are 
already translated to clinics (McKay et al., 2007). 
BMP-2 absorbed on a collagen sponge is approved by 
the United States Food and Drug Administration for 
spinal fusion, tibial non-unions and oral-maxillofacial 
reconstructions (Burkus et al., 2002; Rengachary, 
2002). However, adverse events observed in clinics 
have limited the use of BMP-2, especially for off-label 
applications (Epstein, 2013; Poon et al., 2016; Shields 
et al., 2006; Woo, 2012). These adverse events, mainly 
inflammation (Zara et al., 2011) and swelling (Perri et 
al., 2007), are associated with the supra-physiological 
dose of BMP-2 loaded onto the collagen sponge 
(James et al., 2016), in combination with the strong 
burst release. Half of the loaded BMP-2 is released 
from the collagen sponge in the first 2 d in vivo (Li and 
Wozney, 2001). Possibly, these adverse events can 
be mitigated by using an appropriate release system 
comprising a lower BMP-2 dose (Agrawal and Sinha, 
2016; Mumcuoglu et al., 2017). Such a system might 
broaden the potential use of BMP-2 in orthopaedic 
and maxillofacial surgery applications.
 The dose or concentration of BMP-2 is very 
important for bone formation (Bessa et al., 2008; 
Choi et al., 2016; Yamaji et al., 2007). Since no 
naturally bone-forming cells are present within the 
intradermal environment, subcutaneous ectopic 
bone can only be formed by injecting bone-forming 
cells or an osteoinductive protein, such as BMP-2, 
that can recruit progenitor cells (Scott et al., 2012). 
The concentration or dose of BMP-2 required to 
induce ectopic bone formation depends on the type 
of carrier material used. For example, using 5 µg 
of BMP-2, 32 % bone formation is achieved using 
a 9 mm3 β-tricalcium phosphate scaffold, whereas 
hydroxyapatite, with the same amount of BMP-2, 
only yields 3 % bone formation in a rat ectopic model 
(Tazaki et al., 2009). 5 µg of rhBMP-2, implanted with 
a 6 mm in diameter collagen sponge, are required 
to induce a small intramuscular bone formation in 
mice, with a maximum volume of 5 mm3 (Kim et al., 
2011). 10 mg of silk fibroin particles, loaded with 5 µg 
of BMP-2, induce the formation of a small volume 
(2 mm3) of ectopic bone after 4 weeks in rats (Bessa 
et al., 2010). A low dose of BMP-2 (less than 1 µg), 
delivered on a collagen sponge or with brushite 
calcium-phosphate particles, does not form any bone 
in the palatal submucosa of rats (Martinez-Sanz et al., 
2012), confirming the presence of a threshold dose. 
This threshold depends on the type of material and 
application site and is associated with the release 
kinetics/degradation time of the material and 
subsequent cellular infiltration rate (Bessa et al., 2008).
 An in situ gelling sustained-BMP-2-release 
system, which induces ectopic bone formation, is 
available (Fahmy-Garcia et al., 2016). This hydrogel 
system is based on BMP-2-loaded microspheres, 
composed of a recombinant peptide based on the 
sequence of collagen I (RCP), embedded in a high 
guluronate-type-alginate. The use of RCP allows 
for a reproducible production, without risks of 
disease transmission, which can be associated to 
purified collagen materials. More importantly, RCP 
has excellent cell attachment properties (Parvizi 
et al., 2016) and a specific affinity to bind BMP-2 
(Mumcuoglu et al., 2018), which makes it appealing 
as a controlled release system. The main advantages 
of the developed system are its thixotropic behaviour, 
resulting in easy handling and injectability, good 
BMP-2 release profile and good performance in vivo 
in terms of cellular infiltration, degradation and 
bone formation (Fahmy-Garcia et al., manuscript 
under revision). The aim of the current study was to 
investigate time- and dose-dependent bone formation 
using this BMP-2-releasing hydrogel in an ectopic 
bone formation model and, in addition, to test the 
bone regeneration capacity of two selected doses 
of BMP-2 in an orthotopic model. Formulations 
containing 4 different doses of BMP-2 (10 µg, 3 µg, 
1 µg and 0.3 µg per implant; 50 µg/mL, 15 µg/mL, 
5 µg/mL and 1.5 µg/mL, respectively) and an empty 
control were injected subcutaneously into the dorsum 
of immune-competent rats. Ectopic bone formation 
was followed over a time course of 10 weeks by 
micro-computed tomography (µCT), with histology 
at the endpoint of 10 weeks. To study the spatio-
temporal release of BMP-2 in vivo, formulations 
containing 3 different doses of fluorescently-labelled 
BMP-2 were injected subcutaneously into rats and 
monitored over a time course of 10 weeks by in vivo 
fluorescence imaging. Finally, two doses of BMP-2 
(50 µg/mL and 5 µg/mL) were further investigated in 
a calvarial defect model. For this purpose, 40 µL of 
the composite hydrogel formulation, containing 2 µg 
and 0.2 µg of BMP-2, were injected in 5 mm subcritical 
calvarial defects in immune competent rats and bone 




RCP is a product of Fujifilm, which is commercially 
available as Cellnest™. RCP is produced by the 
genetically modified yeast Pichia pastoris in a 
fermentation process previously described (De Boer 
et al., 2012; Parvizi et al., 2016; Tuin et al., 2010). RCP 
is a 571 amino acids protein, having an isoelectric 
point (pI) of 10.02 and a molecular weight of 51.2 kDa.
 The recombinant human bone morphogenetic 
protein-2 (rhBMP-2, amino acids 283 to 396 plus an 
N-terminal Met-Ala) was expressed in Escherichia 
coli, isolated from inclusion bodies, renatured and 
purified, as previously described (Kirsch et al., 
2000). Lyophilised BMP-2 was dissolved in distilled 
water and the concentration was determined by UV/
Vis spectrophotometry. Freshly dissolved BMP-2 
was used for the experiments. For the fluorescence 
measurements, rhBMP-2 was fluorescently-labelled 
using DyLight™ 800 (ThermoFisher Scientific). For 
the labelling, dissolved BMP-2 solution was adjusted 
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to pH 4.5 by addition of a 2 M sodium acetate (pH 4.5) 
solution. Subsequently, DyLight™ 800 NHS Ester, 
dissolved in dimethyl sulphoxide (DMSO), was 
added in a 5 fold molar excess and the mixture 
was incubated for 4 h at 4 °C while shaking. After 
incubation, the protein was separated from non-
coupled dye by anionic exchange chromatography 
using a HiTrap® SP HP column (GE Healthcare). Since 
the protein could not be eluted even at 2 M sodium 
chloride salt concentration, it was recovered using an 
aqueous 6 M guanidinium hydrochloride solution. 
Subsequently, the protein was dialysed to 1 mM 
hydrochloric acid and finally to distilled water.
 PRONOVA™ SLG20 (sterile alginate, where over 
60 % of the monomer units are guluronate) was 
ordered from NovaMatrix (Sandvika, Norway). The 
properties of the SLG20 alginate are assessed by the 
producer: viscosity (mPa × s): 20-99; approximate 
molecular weight (kDa): 75-150; guluronate/
mannuronate (G/M) ratio: ≥ 1.5; endotoxins (EU/g): 
≤ 100; total viable count [colony forming unit (cfu)/g]: 
sterile (www.novamatrix.biz). Hexamethylene 
diisocyanate (HMDIC), corn oil, sodium chloride, 
calcium carbonate (CaCO3) and glucono delta lactone 
(GDL) were purchased from Sigma-Aldrich. Ethanol, 
acetone and hydrochloric acid were purchased 
from Millipore. The ELISA development kit and 
reagents for BMP-2 quantification were ordered from 
Peprotech (Rocky Hill, NJ, USA). Dulbecco’s modified 
Eagle’s medium (DMEM), foetal bovine serum (FBS) 
and penicillin-streptomycin (P/S) were ordered from 
ThermoFisher Scientific.
RCP microsphere preparation
RCP-calcium carbonate composite microspheres were 
produced by emulsification, as described previously 
(Mumcuoglu et al., 2018). Briefly, a 20 % aqueous RCP 
solution was prepared and mixed with CaCO3 fine 
powder (with a size of < 1 µm) in a 1 : 1 (w/w) ratio. 
This suspension was emulsified in corn oil at 50 °C, 
while stirring the emulsion at 800 rpm for 20 min. 
After cooling down the emulsion, the emulsified 
microspheres were washed three times with acetone. 
After overnight drying at 60 °C, microspheres were 
sieved to 50-72 µm size using sieves from Retsch 
GmbH (Haan, Germany). Subsequently, particles 
were crosslinked by hexamethylene diisocyanate 
(HMDIC) by mixing and stirring of 1 g of spheres 
and 1 mL of HMDIC in 100 mL ethanol for 1 d. 
Non-reacted crosslinker was removed by washing 
several times with ethanol. CaCO3 was left in the 
particles since Ca2+ ions are used to crosslink alginate 
in the final hydrogel formulation. Particles were then 
γ-sterilised at 25 kG (Synergy Health, Etten Leur, 
the Netherlands). The release of BMP-2 from RCP 
microspheres is described by Mumcuoglu et al. (2018).
Preparation of the RCP microsphere-alginate 
hydrogel formulations
SLG-20 alginate was dissolved in 0.9 % sterile sodium 
chloride to create a 2 % w/v solution. 68 mg of sterile 
microspheres were incubated with 170 µL of BMP-2-
containing solution at 4 °C overnight. Initial BMP-2 
concentrations used were 379.4 µg/mL, 113.8 µg/
mL, 37.9 µg/mL and 11.4 µg/mL, to yield final 
BMP-2 concentrations in the hydrogel formulation 
of 50 µg/mL, 15 µg/mL, 5 µg/mL and 1.5 µg/mL, 
respectively. Next day, when all BMP-2-containing 
liquid was absorbed, 1014 µL of the 2 % w/v SLG20 
solution were added and the swollen microspheres 
were resuspended. Then, 106 µL of 0.06 M fresh 
GDL solution were added and mixed immediately. 
GDL was used to dissolve minute amounts of 
CaCO3, thereby crosslinking alginate and increasing 
the mechanical property of the formulation. The 
formulations were thoroughly mixed, passed 
through a 19 G needle immediately after addition 
of all components and stored overnight at 4 °C to 
equilibrate. Next day, the prepared formulations 
were mixed again prior to use.
In vitro release of BMP-2 from hydrogel 
formulations
Hydrogel formulations were prepared as described 
above, containing either fluorescently-labelled or 
wild-type BMP-2. Since these experiments had the 
objective to study only BMP-2 release, the biological 
activity of these proteins was not tested. 200 µL 
of each hydrogel were added to each well of a 24-
well plate, inserts with a 0.4 µm pore size. 1 mL of 
DMEM supplemented with 10 % FBS and 1 % P/S 
per well was added to the reservoir plate. The plates 
were incubated at 37 °C under constant agitation at 
300 rpm. At each time point, all medium (1 mL) was 
collected from the reservoir plate and changed with 
fresh medium (1 mL). Positive controls were 10 µg, 
3 µg or 1 µg of wild type or fluorescently-labelled 
BMP-2 in 1 mL DMEM. At every time point, 100 µL 
of these positive controls were sampled. The collected 
release media and control samples were analysed 
using the rhBMP-2 ELISA development kit, according 
to manufacturer’s protocol. To calculate the fraction 
released at each time point, the concentrations 
detected in the release medium of the hydrogel 
samples were normalised to the concentrations of the 
positive controls, to correct for loss by adsorbance to 
the tube and/or degradation of the protein.
Study design and ethics
All animal experiments were performed with prior 
approval of the Erasmus Medical Centre ethics 
committee for laboratory animal use (project number: 
AVD101002015114 and protocol numbers: EMC 
15-114-03 and EMC 15-114-04). 10-week-old male 
Sprague Dawley (SD) rats (Charles River) were 
used. The animals were randomly assigned and 
housed in pairs in specific-pathogen-free conditions 
and allowed to adapt to the conditions of the animal 
house for 7 d before implantation. The animals were 
maintained at 22 ± 5 °C on a 12 h dark/light cycle with 
access to standard rat chow and water ad libitum. 10 
weeks after implantation, animals were euthanised 
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with CO2 and the specimens were harvested for µCT 
analysis and histology.
Subcutaneous injection of in situ gelling 
formulations to study ectopic bone formation
To evaluate the effect of different doses of BMP-2 on 
ectopic bone formation, the hydrogel compositions 
were subcutaneously injected (total volume: 200 µL 
per injection) into the dorsum of the rats (20 rats 
in total). Each animal received 4 or 5 randomly 
assigned injections. All injections were performed 
on animals under isoflurane inhalation. To study 
the BMP-2-dose effect on bone formation, 4 different 
BMP-2 concentrations were used (50, 15, 5 and 
1.5 µg/mL), resulting in total doses of 10 µg, 3 µg, 
1 µg and 0.3 µg BMP-2 per implant (n = 8 per 
group), respectively. As a control, alginate with 
microspheres, but without BMP-2 was injected (n = 6). 
To investigate the spatio-temporal distribution of 
BMP-2 in the implanted material in vivo, 200 µL of 
hydrogel containing fluorescently-labelled BMP-2 
were injected at different doses: 10 µg, 3 µg and 1 µg 
(n = 6). Longitudinal imaging was performed by µCT 
and in vivo imaging instruments (IVIS) biweekly until 
the end of the experiment (10 weeks).
Calvarial defect model to study bone regeneration 
with in situ gelling formulations
To evaluate the effect of two hydrogel formulations 
with a selected dose of BMP-2 on orthotopic bone 
formation, two defects of 5 mm in diameter were 
created in the rat calvaria (18 rats in total). Prior to the 
surgery, animals received intraperitoneal injections 
of 0.05 mg/kg buprenorphine (Temgesic®; Indivior, 
Slough, UK) and 5 mL/kg sterile normal saline to 
account for fluid loss. Surgeries were performed 
under 2.5 % isoflurane anaesthesia. The animal skulls 
were shaved and disinfected with ethanol swabs. 
Then, an incision was made through the skin of the 
calvarium and the periosteum and full-thickness 
flaps were reflected. The defect was irrigated along 
the sagittal midline of the skull with 0.1 mL of 1 % 
xylocaine with 1 :  200,000 epinephrine (AstraZeneca). 
Under copious sterile saline irrigation, two 5 mm in 
diameter bone defects were drilled in each animal 
using a micro trephine drill (Fine Science Tools, 
Heidelberg, Germany) and any visible debris or 
bone chips were removed. Then, 40 µL of hydrogel 
formulation with BMP-2 or, as a control, without 
BMP-2 were injected into the defect. As sham control, 
empty defects were used (5 rats, 10 defects). As a 
biomaterial control, alginate with microspheres were 
injected into the defects (5 rats, 10 defects). Alginate 
with microspheres loaded with 50 µg/mL BMP-2 (3 
rats, 3 defects) was used to study healing with a high 
BMP-2 dose; alginate with microspheres loaded with 
5 µg/mL (5 rats, 10 defects) was used to study healing 
with a low BMP-2 dose. The animal number of the 
50 µg/mL BMP-2 cohort was kept small because it 
was expected to induce bone formation, based on the 
results of a previous ectopic bone formation study 
(Fahmy-Garcia et al., manuscript under revision). 
After implantation, the periosteum and the skin 
above the defects were repositioned and sutured with 
polylactic acid sutures (Vycril 4.0, Ethicon, Johnson 
& Johnson, São José dos Campos, Brazil). During the 
next 3 d, all animals received three postoperative 
doses of buprenorphine for analgesia every 10 h. 
Longitudinal imaging was performed biweekly by 
µCT until week 10. 10 weeks after implantation, 
animals were euthanised with CO2 and the specimens 
were harvested for µCT analysis and histology.
µCT imaging
µCT (Quantum FX, PerkinElmer) was used to image 
animals 1, 2, 4, 6, 8 and 10 weeks after injection and 
the implants retrieved at week 10. To image the 
ectopic bone in vivo, the following parameters were 
used: field of view, 73 mm; voltage, 90 kV; current, 
160 µA; scan time, 120 s; resolution, 148 µm. To 
image the retrieved ectopic bone field of view of 
20 mm, scan time of 120 s and resolution of 40 µm 
were used. To image the calvarial defects, a 30 mm 
field of view, scan time of 3 min and resolution of 
59 µm were used. The trabecular and cortical bone 
mineral density (BMD) were determined based on 
the calibration scanning, using two phantoms with 
known density (0.25 g/cm3 and 0.75 g/cm3; Bruker 
MicroCT) measured under identical conditions. For 
image processing, Analyze software version 11.0 was 
used (Mayoclinic, Rochester, MN, USA). Threshold 
levels were set to 0.11 g/cm3, 400 Hounsfield units.
Fluorescence imaging in vivo
An IVIS Imaging System 200 (PerkinElmer) was used 
to image fluorescent BMP in the animals immediately 
after the injection, 3 d and 1, 2, 4, 6, 8 and 10 weeks 
after injection. The following imaging parameters 
were used: exposure time, 20 s; excitation, 745 nm; 
emission, 820 nm and 840 nm. For the image analysis, 
the region of interest for each implant was selected 
as a circle with an area of 3.0 ± 0.1 cm2 and the total 
radiant efficiency [(p/s)/(µW/cm2)] was calculated by 
the Living Image® software (PerkinElmer). A region 
of interest of 3 cm2 was selected since this was the 
magnitude of the area where the signal was detected 
directly after injection.
Histology
For histological analysis of the subcutaneous 
ectopic bone formation, specimens were fixed in 
4 % formalin solution for 48 h and decalcified with 
10 % ethylenediaminetetraacetic acid (EDTA) for 
2-4 weeks. Implants were dehydrated in graded 
ethanol solution from 70 % to 100 % and embedded 
in paraffin. 6 µm-thick sections were prepared using 
a Leica microtome and mounted on subbed glass 
slides (ThermoFisher Scientific). Three cross sections, 
at least 200 µm apart from each other, were collected 
from each implant. The sections were deparaffinised 
and rinsed with distilled water to be stained with 
haematoxylin and eosin (H&E). For calvaria samples, 
246 www.ecmjournal.org
D Mumcuoglu et al.                                                                                          Controlled induction of bone formation
10 weeks after implantation, the relevant part of the 
skull was removed and fixed in neutral buffered 
4 % formalin solution for 3 d, dehydrated in graded 
ethanol solution from 70 % to 100 % and embedded 
in methyl methacrylate resin. 10 µm-thick sections 
were generated along the long axis of the cylindrical 
samples on a saw microtome system (Leica 4 SP1600). 
Samples were stained with von Kossa and Goldner’s 
trichrome stainings, as previously described (Gruber, 
1992; van der Eerden et al., 2013). The sections were 
imaged by NanoZoomer-XR (Hamamatsu, Japan).
Statistical analysis
The quantitative µCT data of retrieved ectopic 
bone were analysed using one-way analysis of 
variance (ANOVA) and a Bonferroni post-hoc 
multiple comparison test. In vivo calvaria µCT data 
were analysed using two-way analysis of variance 
(ANOVA) and a Bonferroni post-hoc multiple 
comparison test. A value of p < 0.05 was considered 
statistically significant. Linear regression analysis of 
µCT data was performed by GraphPad, to analyse 
the time-dependent bone formation.
Results
BMP-2 was retained for at least 4 weeks in vivo
To monitor the retention of BMP-2 in vivo, composite 
hydrogels (alginate with RCP microspheres), with 
three different doses of fluorescently-labelled BMP-
2, were used. First, it was confirmed in vitro that the 
release of fluorescently-tagged (fluo) BMP-2 from the 
hydrogels was similar to wild type BMP-2 (Fig. 1). The 
difference between the release of the two proteins was 
less than 10 %, showing that labelled protein could 
be used to study retention of BMP-2 in vivo. Then, 
the fluorescence signal (shown as radiance efficiency) 
of the 3 doses injected subcutaneously was followed 
in vivo by fluorescence imaging. The fluorescence 
signal generated by the three different BMP-2 doses 
decreased until week 4 (Fig. 2). After 4 weeks, all 
fluorescence curves levelled off. Interestingly, the 
fluorescence values did not drop to the background 
value, indicating the presence of some remaining 
BMP-2 in the hydrogels. The curves corresponding 
to the different doses were not significantly different 
due to high variation among the animals (Fig. 2).
Microspheres with alginate hydrogel induced 
BMP-2 dose-dependent ectopic bone formation
The effect of the BMP-2 dose on subcutaneous ectopic 
bone formation was investigated over a period of 10 
weeks using 4 different BMP-2 doses (representative 
µCT images are shown in Fig. 3a). At the 10-week 
endpoint, the bone volume formation resulted to 
be dose-dependent (Fig. 3b). The highest dose of 
10 µg (50 µg/mL) induced the largest volume of 
ectopic bone formation, while the lowest doses of 
0.3 µg (1.5 µg/mL) and 0 µg of BMP-2 failed to form 
bone. The composite hydrogel containing 1 µg of 
BMP-2 (5 µg/mL) formed just a minute bone volume, 
indicating that this dose was the threshold of ectopic 
bone induction in rats for this composite hydrogel. 
The bone mineral density of the formed bone did not 
differ significantly (Fig. 3c): 0.5 g/cm3 for 3 µg and 
10 µg of BMP-2 and 0.35 g/cm3 for 1 µg of BMP-2. 
For comparison, tibiae were extracted and imaged 
using the same instrumental settings. The cortical 
and trabecular bone of the tibiae had a density 
between 1.2-2.0 g/cm3 and 0.15-0.5 g/cm3, respectively, 
showing that ectopic bone formed subcutaneously 
had a density in the range of trabecular bone.
Microspheres with alginate hydrogel containing 
different doses of BMP-2 showed different 
kinetics of bone formation
Longitudinal µCT imaging of rats for 10 weeks 
revealed a dose-dependent rate of ectopic bone 
formation (Fig. 4a,b). The volume of ectopic bone in 
the 10 µg of BMP-2 group increased linearly between 
week 1 and week 8, with a rate of 16.9 ± 0.8 mm3/
week (r2 = 0.99), after which a plateau was reached. 
A 10-week endpoint was decided upon, based on the 
longitudinal µCT imaging. Ectopic bone volume did 
not increase between 8 and 10 weeks for the highest 
dose; therefore, the experiment was ended at 10 
weeks. In the 3 µg of BMP-2 group, a two-phase linear 
trend was observed. Between 2 and 6 weeks, a linear 
increase in bone volume, with a rate of 10.2 ± 0.5 mm3/
week (r2 = 0.99), was observed, while a slower linear 
trend was detected between 6 and 10 weeks, with a 
Fig. 1. In vitro release of fluorescently-labelled and non-labelled BMP-2 from the RCP microspheres with 
alginate hydrogel, showing no major difference between labelled and non-labelled BMP-2 release in vitro 
in DMEM with 10 % FBS and 1 % P/S.
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Fig. 2. (a) BMP-2 was retained in the RCP microspheres with alginate hydrogels in vivo for at least 4 weeks. 
The total radiance efficiency of the fluorescence signal was shown for three different doses of fluorescent 
BMP-2- (10 µg, 3 µg and 1 µg) containing RCP microspheres with alginate that were injected subcutaneously 
in SD rats (n = 6 injections). (b) Representative image of in vivo fluorescence imaging.
Fig. 3. Ectopic bone formation at 10 weeks was BMP-2 dose-dependent. (a) Representative images of 
µCT of implants retrieved at 10 weeks. (b) Volume of ectopic bone in mm3. (c) Bone mineral density after 
thresholding to 0.11 g/cm3, 400 Hounsfield units. (a,b,c) Five different doses of BMP-2- (10 µg, 3 µg, 1 µg, 
0.3 µg and 0 µg) containing RCP microspheres with alginate (200 µL) were injected subcutaneously in 
SD rats (n = 8 injections). Data are shown as mean ± SD, one-way ANOVA was performed to compare 
treatment groups. ** p < 0.05, *** p < 0.001.
rate of 3.4 ± 0.4 mm3/week (r2 = 0.99). Although the 
amount of ectopic bone formed by 1 µg of BMP-2 was 
very small, with a volume of only 3.0 ± 5.5 mm3 (mean 
± SD) at week 10, the bone volume linearly increased 
between 1 week and 10 weeks (rate = 0.36 ± 0.1 mm3/
week, r2 = 0.96).
 Significant mineralisation could be observed 
after 2 weeks (Fig. 4c). A linear increase in bone 
density was seen with 10 µg of BMP-2 between 2 
and 10 weeks, with a rate of 0.025 ± 0.002 g/cm3 per 
week (r2 = 0.98). In contrast to the bone volume, the 
mineral density did not reach a plateau at 10 weeks, 
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suggesting that mineralisation could continue for 
longer than 10 weeks. Similarly, 3 µg of BMP-2 
showed a linear increase in bone density between 
2 and 10 weeks, with a rate of 0.019 ± 0.002 g/cm3 
(r2 = 0.96). The 1 µg-BMP-2-comprising hydrogel 
clearly mineralised slower than the other two doses, 
with a rate of only 0.005 ± 0.001 g/cm3 (r2 = 0.97).
Ectopic bone formation was confirmed by 
histology
The morphology of ectopic bone induced by five 
different doses of BMP-2- (10 µg, 3 µg, 1 µg, 0.3 µg 
and 0 µg) containing hydrogel was evaluated by 
histology at week 10. Bone tissue could be identified 
for the 10 µg, 3 µg and 1 µg of BMP-2-comprising 
hydrogels and no bone was found for the two lowest 
doses of 0.3 µg and 0 µg. The largest area of ectopic 
bone was found in the 10 µg samples (Fig. 5), thereby 
confirming the µCT data (Fig. 3). Interestingly, for 
all BMP-2 doses, remnants of microspheres and 
gels could be observed, indicating that the implants 
were not yet fully degraded after 10 weeks. This 
result was in line with the long-term retention of 
BMP-2, as observed by fluorescence imaging. Bone 
formation was not only observed at the periphery 
of the hydrogel, but also in some samples within 
the hydrogel construct. Microspheres were also 
observed within the hydrogel construct. Some of 
the microspheres were intact, some were infiltrated 
with cells. The infiltrated microspheres changed 
the spherical morphology, probably as a sign of 
degradation. Small ossicles were detected around 
some microspheres. Also, around the implants, a 
layer of fibrous tissue was observed, which is a typical 
foreign body response upon implantation (Morais et 
al., 2010).
Microspheres with alginate hydrogel containing 
50 µg/mL BMP-2 induced bone formation in a rat 
calvarial defect model
The regeneration capacity of the composite hydrogels 
loaded with BMP-2 was tested in a subcritical-sized 
calvarial defect model. Biomaterial only, 5 µg/
mL or 50 µg/mL BMP-2-loaded biomaterials were 
injected into a 5 mm calvarial defect and empty 
defect (sham) was used as a control (Fig. 6a). The 
bone volume with 50 µg/mL BMP-2 was significantly 
larger than in all other groups (Fig. 6b), showing 
the regenerative capacity of this concentration of 
BMP-2 in the composite hydrogel formulation. 
The low concentration (5 µg/mL) did not form any 
additional bone as compared to the biomaterial only 
or empty defect (sham) control. Interestingly, the 
bone volume of the empty defect was slightly higher 
at week 2 as compared to the biomaterial only, albeit 
the difference was not statistically significant. At 
the end of the experiment, biomaterial and empty 
defect groups produced similar bone volumes. The 
bone mineral density gradually increased over time 
(Fig. 6c). At week 2, 50 µg/mL BMP-2 had a lower 
density when compared to 5 µg/mL BMP-2. This 
effect reversed later at week 8 and 10, when 50 µg/
mL BMP-2 induced higher density as compared to 
5 µg/mL-BMP-2-treated group. von Kossa staining 
and Goldner’s trichrome staining on the calvaria 
confirmed the regeneration of the bone defect 
Fig. 4. Ectopic bone volume and density increase over the time course of 10 weeks was BMP-2 dose-
dependent. (a) Representative µCT images of bone formed by 10 µg of BMP-2 administration over 10 
weeks. (b) Volume of ectopic bone in mm3 after thresholding. (c) Mineral density of bone in g/cm3 after 
thresholding. Threshold was set to 0.035 g/cm3 to discriminate mineralised tissue from soft tissue. (a,b,c) 
Five different doses of BMP-2- (10 µg, 3 µg, 1 µg, 0.3 µg and 0 µg) containing RCP microspheres with 
alginate were injected subcutaneously in SD rats (n = 8 injections). Data are shown as mean ± SD. Since 
0.3 µg and 0 µg BMP-2 did not form any bone, they are not represented in this figure.
D Mumcuoglu et al.                                                                                          Controlled induction of bone formation
249 www.ecmjournal.org
(Fig. 7). Empty defect, biomaterial control or low 
concentration (5 µg/mL) did not bridge the bone 
defect at week 10. The 50 µg/mL BMP-2 concentration 
was effective in bridging the 5 mm calvarial defect.
Discussion
This study aimed at investigating the use of a slow 
release system to lower the effective BMP-2 dose, the 
effect on ectopic bone formation of the BMP-2 dose 
delivered by an in situ gelling hydrogel formulation 
and the bone repair capacity of two selected doses of 
BMP-2. The composite hydrogel provided sustained 
release of BMP-2 for 4 weeks, as shown in vivo by 
fluorescence imaging. Ectopic bone was formed for 
three different doses of BMP-2 (50, 15 and 5 µg/mL 
in a 200 µL implant) in a dose- and time-dependent 
manner, with the highest BMP-2 dose showing the 
fastest bone growth and highest bone volume at 10 
weeks. The bone-forming dose of 50 µg/mL (2 µg per 
implant in a 5 mm defect) was confirmed to be also 
effective in a subcritical calvarial bone defect model.
 The BMP-2 delivery system used was selected 
based on a previous study where a hydrogel 
composed of SLG alginate and BMP-2-loaded 
RCP-microspheres provide superior ectopic bone 
formation as compared to other hydrogel formulations 
(Fahmy-Garcia et al., manuscript under revision). 
The advantages of this delivery system are the easy 
handling (due to its thixotropic behaviour), the 
sustained BMP-2 release profile and the presence of 
cell attachment sites (due to the RCP microspheres). 
Differently from other injectable hydrogel systems, 
e.g. the hydrogel developed by Seo et al. (2017), 
the used system contains RCP microspheres that 
have excellent cell attachment properties (Parvizi 
et al., 2016) and a specific binding affinity to BMP-2 
Fig. 5. Bone formation was confirmed by histology. H&E staining for (a) 10 µg, (c) 3 µg, (d) 1 µg, while no 
bone was observed for (e) 0.3 µg and (f) 0 µg of BMP-2-containing RCP microsphere with alginate gels. 
(b) A closer representation of the 10 µg of BMP-2 sample showing bony tissue around microspheres. RCP 
microspheres (MS), alginate hydrogel (Alg.), bone formation (B) and fibrous tissue (FT) are indicated. 
Scale bar is 250 µm for a,c,d,e,f and 100 µm for b. Scale bars of the insert images are 2.5 mm and red boxes 
indicate the area of high magnification.
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Fig. 6. (a). Representative µCT images of calvaria (superior view) at week 10 after surgery and implantation. 
(b). Bone volume showing the regeneration of calvarial defects over 10 weeks. The bone volume of 
50 µg/mL BMP-2-containing biomaterial was significantly higher at all time points as compared to 5 µg/
mL BMP-2, biomaterial and empty defect groups (** p < 0.01 or *** p < 0.001). (c) Bone density showing 
the regeneration of calvaria over 10 weeks. Bone density induced by 50 µg/mL BMP-2 was lower than 
that of 5 µg/mL BMP-2 group at week 2 (* p < 0.05). At week 8 and 10, density of induced bone tissue 
was higher in 50 µg/mL BMP-2 than 5 µg/mL BMP-2 group (* p < 0.05). Treatment groups were empty 
control (n = 10), biomaterial only (n = 10), 5 µg/mL BMP-2-containing biomaterial (n = 10) and 50 µg/mL 
BMP-2-containing biomaterial (n = 3). Data are shown as mean ± SD, two-way ANOVA was performed 
to compare treatment groups.
Fig. 7. The first two rows show von Kossa staining, the lower row Goldner’s trichrome staining of the 
calvarial defect samples. From left to right: 50 µg/mL BMP-2, 5 µg/mL BMP-2, biomaterial control and 
empty defect. Bone healing and bridging of the defect was confirmed for the 50 µg/mL BMP-2 group. 
Red boxes indicate the area of the defect. Scale bars of the first row are 2.5 mm, second and third row are 
250 µm. B: bone; CT: connective tissue.
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(Mumcuoglu et al., 2018). In the current study, it was 
shown that in situ gelling hydrogel composite with a 
concentration of 50 ug/mL BMP-2 (2 µg per implant 
in a 5 mm defect) successfully regenerated bone. In 
other preclinical studies with BMP-2 carriers, the 
BMP-2 dose needed to heal a critical sized defect is 
generally higher; in a rat calvarial model similar to 
the one used in the current study, complete healing 
of the defects is achieved with poly lactic-co-glycolic 
acid (PLGA) membranes adsorbed with 5 mg/mL of 
BMP-2 (Ono et al., 2013). Young et al. (2009), using 
a 8 mm rat calvarial model and 0.5 µg and 1 µg of 
BMP-2 per implant delivered with gelatin particles, 
show an incomplete bone bridging. Partial healing 
of 8 mm rat calvarial defects of approximately 20 % 
and 60 % is observed with a composite comprising 
segmented polyurethane, poly[lactic-co-glycolic acid] 
and β-tricalcium phosphate loaded with 1.6 µg and 
6.5 µg of rhBMP-2, respectively (Rodriguez-Evora 
et al., 2013). Besides, other BMP-2 carriers induce 
lower ectopic bone volumes. For example, silk fibroin 
(2 mm3) (Bessa et al., 2010) and collagen sponge 
(5 mm3) (Kim et al., 2011) form a max of 5 mm3 of 
ectopic bone using 5 µg of BMP-2, which is lower than 
the 41 mm3 induced with 3 µg (15 µg/mL) of BMP-2, 
as done in the current ectopic model. In a composite 
gelatin microsphere, biphasic calcium phosphate 
hydrogel system, 13 mm3 of ectopic bone are achieved 
with 100 µg/mL BMP-2 (Poldervaart et al., 2013). 
Considering these earlier studies, the current study 
showed that the in situ gelling formulation of the 
RCP microspheres with alginate is a promising BMP-
2 delivery system that might reduce the required 
effective dose of BMP-2 and, thus, potentially mitigate 
the adverse effects of BMP-2.
 Besides the required threshold or effective 
dose of BMP-2, the hydrogel matrix – to which the 
characteristics of the biomaterial, such as release, 
integrity, degradation and cell infiltration, should 
be aligned – also affects the bone formation process. 
Factors such as speed of bone formation, amount and 
location of the formed bone are important to consider. 
The natural fracture healing process requires around 
4 weeks in rodents (Einhorn and Gerstenfeld, 2015) 
and it can take up to 3-4 months in humans (Garcia 
et al., 2013). In the used ectopic model, the kinetics 
of bone formation was shown to be linear for the 
10 µg of BMP-2 group, between week 1 and 8, while 
the main release of BMP-2 was observed in the first 
4 weeks, both processes matching the time frame of 
natural bone healing processes (Marsell and Einhorn, 
2011). Interestingly, after 4 weeks, a small portion of 
BMP-2 was retained inside the hydrogel, probably 
due to the strong interaction between BMP-2 and 
the RCP microspheres (Mumcuoglu et al., 2018). This 
portion of BMP-2 will only be released upon further 
degradation of the material and could probably 
contribute to the bone volume increase after 4 weeks. 
The main determinant of BMP-2 release in vivo is 
the specific interaction and the degradation of the 
particles. The RCP amino acid sequence will most 
probably be a main contributor to the release profile, 
although it is not possible to exclude that polarity and 
ionic strength will also affect the release profile of 
proteins by changing the interaction with the matrix. 
With 10 µg of BMP-2, ectopic bone volume reached a 
plateau at week 8. This suggested that bone formation 
could be confined to the hydrogel area. Therefore, 
this hydrogel formulation might eliminate the risk of 
excessive surrounding soft tissue calcification, which 
is a major concern in currently used BMP-2-based 
therapies (James et al., 2016).
 The ectopic model results indicated that hydrogels 
containing 3 µg and 10 µg of BMP-2 were not only 
forming bone at the periphery of the implants, but in 
the entire implants. Qualitative analysis of 3D µCT 
images revealed that the bone formation started at 
different locations throughout the implant around 
week 2. These results corroborated previous findings 
(Fahmy-Garcia et al., manuscript under revision), 
according to which the hydrogel allows bone-forming 
cells to infiltrate the gel at early time points.
 Interestingly, hydrogels without or with a very 
low dose of BMP-2 seemed to slightly, though not 
significantly, impede bone formation in the calvarial 
defect model at the early time points when compared 
to the empty control. After 10 weeks, bone formation 
in defects filled with biomaterial, without or with 
a low dose of BMP-2, was not different from the 
empty defect control. It is possible that the empty 
defect induced higher initial inflammation and faster 
infiltration of inflammatory cells as compared to 
the RCP microspheres with alginate and, therefore, 
the healing process started earlier. The safety of the 
separate components of this system are verified by 
Novamatrix and Fujifilm. On their website (www.
novamatrix.biz), toxicology studies of alginate are 
reported. The biocompatibility of RCP is confirmed 
in a previous study by Parvizi (2016). Histological 
analysis of the samples at week 10 showed infiltrated 
cells in the defect area for both defects filled with 
biomaterials and empty control. These cells were 
mainly macrophages. A hydrogel-dependent cellular 
response of different hydrogels in ectopic bone 
formation is already shown (Fahmy-Garcia et al., 
manuscript under revision). For the SLG alginate gel 
selected for this study, the number of inflammatory 
cells is initially high and decrease at later time points 
(Fahmy-Garcia et al., manuscript under revision). 
Alginate is known for poor cell attachment (Rowley 
et al., 1999; Sarker et al., 2014). Possibly, alginate 
slightly delays cell infiltration as compared to natural 
bone healing environment where there is a fibrin 
clot hosting the infiltrated cells. These effects could 
be object of a future study. However, as differences 
did not reach statistical significance and the endpoint 
healing for both groups was similar, an inhibitory 
effect of the hydrogel matrix on the overall bone 
healing is not expected. Overall, the benefit of having 
a slow release system outweighs this minor effect, 
since the BMP condition healed much better than the 
control.
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Conclusion
The injectable slow BMP-2 release delivery system 
resulted in a time- and dose- dependent bone 
formation in an ectopic and orthotopic model. 
This delivery system, composed of alginate and 
RCP microspheres, provided sustained release of 
BMP-2, favoured cell attachment and induced bone 
formation at a relatively low dose of BMP-2, making 
it promising for bone regeneration therapies.
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Discussion with Reviewers
Declan Devine: The animal model utilised was a 
calvarial model, which is a non-loaded bone, whereas 
BMP-2 is marketed for use in loaded environments. 
What effect would loading have on the scaffold 
properties, breakdown and release rate of BMP-2?
Authors: Mechanical loading is a very important 
parameter for the regeneration of load-bearing bones 
(Tobias, 2015, additional reference). According to 
rheology data (Fahmy-Garcia et al., manuscript under 
revision), alginate with microspheres is a thixotropic 
hydrogel, showing that under shear stress (500 % 
strain) the gel to solution transition occurs: in other 
words, the gel becomes a viscous liquid. When the 
stress is removed, the hydrogel recovers again as a 
result of self-healing property. Since the mechanical 
properties of these hydrogels are far lower than that 
of bone and they show thixotropic behaviour, they 
are not good candidates for treatment of load-bearing 
bones unless used in combination with fixation 
techniques, such as using plates and screws, or in 
combination with stiffer materials. In addition, the 
BMP-2 release may vary under mechanical loading, 
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as proposed in a non-human primate study on spinal 
arthrodesis, in which a BMP-2-loaded collagen 
sponge prevents bone induction probably due to 
squeezing of proteins out of the sponge (Martin 
et al., 1999, additional reference). Thus, additional 
studies would be required with this material into a 
load-bearing defect.
Nunzia Di Maggio: May BMP-2 be combined to 
other growth factors in the same hydrogel? Would 
you comment on which other processes would be 
most useful to target to maximise efficient bone 
regeneration?
Authors: BMP-2 can be combined with other growth 
factors or cytokines in the same hydrogel. There are 
various processes that can be targeted to maximise 
bone formation. Vascularisation is, for example, a 
very important process in bone formation. Newly 
formed bone should be vascularised to support the 
process of regeneration, calcification etc.. Vascular 
endothelial growth factor-A (VEGF-A) (Hu and 
Olsen, 2016, additional reference) or another factor 
that can increase vascularisation can also be used 
within this hydrogel. Also, combinations of BMP-2 
and BMP-7 might be interesting: sequential delivery 
of both factors increases new bone formation (Jo et 
al., 2015, additional reference).
Nunzia Di Maggio: For which clinical scenarios 
would you envision this injectable hydrogel to be 
most suitable?
Authors: The applications of the hydrogels in non-
load-bearing bones, such as calvarium or around the 
orbital cavity and in small defects in the mandibular 
or jaw bones in the maxillofacial surgery, are possible 
(Jayaram et al., 2017, additional reference). There are 
several specific examples that applications of tissue 
engineering products are suitable. For example, 
for maxillary reconstruction of flap after a large 
keratocyst, a biomaterial can be used (Mesimaki et al., 
2009, additional reference). Another application can 
be in jaw bones with osteolytic lesions (Dominijanni 
et al., 2012, additional reference). The reconstruction 
of critical size mandibular bone defects is a challenge 
in oral and maxillofacial surgery. For this application, 
scaffolds are tested (Ren et al., 2005; Yuan et al., 2007, 
additional reference) and the hydrogel presented 
in this study could be a potential material for this 
application. Another potential application is sinus 
augmentation, which is performed before dental 
implant surgery in case of bone loss (Schimming and 
Schmelzeisen, 2004; Springer et al., 2006, additional 
reference).
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